BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 34198326)

  • 1. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease.
    Canal B; McClure AW; Curran JF; Wu M; Ulferts R; Weissmann F; Zeng J; Bertolin AP; Milligan JC; Basu S; Drury LS; Deegan TD; Fujisawa R; Roberts EL; Basier C; Labib K; Beale R; Howell M; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2445-2464. PubMed ID: 34198326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase.
    Basu S; Mak T; Ulferts R; Wu M; Deegan T; Fujisawa R; Tan KW; Lim CT; Basier C; Canal B; Curran JF; Drury LS; McClure AW; Roberts EL; Weissmann F; Zeisner TU; Beale R; Cowling VH; Howell M; Labib K; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2481-2497. PubMed ID: 34198328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification.
    Baddock HT; Brolih S; Yosaatmadja Y; Ratnaweera M; Bielinski M; Swift LP; Cruz-Migoni A; Fan H; Keown JR; Walker AP; Morris GM; Grimes JM; Fodor E; Schofield CJ; Gileadi O; McHugh PJ
    Nucleic Acids Res; 2022 Feb; 50(3):1484-1500. PubMed ID: 35037045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp15 endoribonuclease.
    Canal B; Fujisawa R; McClure AW; Deegan TD; Wu M; Ulferts R; Weissmann F; Drury LS; Bertolin AP; Zeng J; Beale R; Howell M; Labib K; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2465-2479. PubMed ID: 34198324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase.
    Bertolin AP; Weissmann F; Zeng J; Posse V; Milligan JC; Canal B; Ulferts R; Wu M; Drury LS; Howell M; Beale R; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2425-2443. PubMed ID: 34198323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry.
    Pearson LA; Green CJ; Lin D; Petit AP; Gray DW; Cowling VH; Fordyce EAF
    SLAS Discov; 2021 Jul; 26(6):749-756. PubMed ID: 33724070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase.
    Zeng J; Weissmann F; Bertolin AP; Posse V; Canal B; Ulferts R; Wu M; Harvey R; Hussain S; Milligan JC; Roustan C; Borg A; McCoy L; Drury LS; Kjaer S; McCauley J; Howell M; Beale R; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2405-2423. PubMed ID: 34198322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the SARS-CoV-2 NSP14 3'-5' exoribonuclease by NSP10 and response to antiviral inhibitors.
    Riccio AA; Sullivan ED; Copeland WC
    J Biol Chem; 2022 Jan; 298(1):101518. PubMed ID: 34942146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease.
    Milligan JC; Zeisner TU; Papageorgiou G; Joshi D; Soudy C; Ulferts R; Wu M; Lim CT; Tan KW; Weissmann F; Canal B; Fujisawa R; Deegan T; Nagaraj H; Bineva-Todd G; Basier C; Curran JF; Howell M; Beale R; Labib K; O'Reilly N; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2499-2515. PubMed ID: 34198327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry.
    Scholle MD; Liu C; Deval J; Gurard-Levin ZA
    SLAS Discov; 2021 Jul; 26(6):766-774. PubMed ID: 33870746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New targets for drug design: importance of nsp14/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2.
    Saramago M; Bárria C; Costa VG; Souza CS; Viegas SC; Domingues S; Lousa D; Soares CM; Arraiano CM; Matos RG
    FEBS J; 2021 Sep; 288(17):5130-5147. PubMed ID: 33705595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs.
    Narayanan N; Nair DT
    Int J Biol Macromol; 2021 Jan; 168():272-278. PubMed ID: 33309661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target.
    Rona G; Zeke A; Miwatani-Minter B; de Vries M; Kaur R; Schinlever A; Garcia SF; Goldberg HV; Wang H; Hinds TR; Bailly F; Zheng N; Cotelle P; Desmaële D; Landau NR; Dittmann M; Pagano M
    Cell Death Differ; 2022 Feb; 29(2):285-292. PubMed ID: 34862481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19.
    Perveen S; Khalili Yazdi A; Devkota K; Li F; Ghiabi P; Hajian T; Loppnau P; Bolotokova A; Vedadi M
    SLAS Discov; 2021 Jun; 26(5):620-627. PubMed ID: 33423577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Author's overview: identifying SARS-CoV-2 antiviral compounds.
    Diffley JFX
    Biochem J; 2021 Jul; 478(13):2533-2535. PubMed ID: 34198320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of SARS-CoV-2 nsp10 bound to nsp14-ExoN domain reveals an exoribonuclease with both structural and functional integrity.
    Lin S; Chen H; Chen Z; Yang F; Ye F; Zheng Y; Yang J; Lin X; Sun H; Wang L; Wen A; Dong H; Xiao Q; Deng D; Cao Y; Lu G
    Nucleic Acids Res; 2021 May; 49(9):5382-5392. PubMed ID: 33956156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease.
    Lim CT; Tan KW; Wu M; Ulferts R; Armstrong LA; Ozono E; Drury LS; Milligan JC; Zeisner TU; Zeng J; Weissmann F; Canal B; Bineva-Todd G; Howell M; O'Reilly N; Beale R; Kulathu Y; Labib K; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2517-2531. PubMed ID: 34198325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
    Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S
    Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.
    Choi R; Zhou M; Shek R; Wilson JW; Tillery L; Craig JK; Salukhe IA; Hickson SE; Kumar N; James RM; Buchko GW; Wu R; Huff S; Nguyen TT; Hurst BL; Cherry S; Barrett LK; Hyde JL; Van Voorhis WC
    PLoS One; 2021; 16(4):e0250019. PubMed ID: 33886614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.